Towards Precision Epilepsy Treatment: Ion Channels and TMS-EEG

How do you know whether a new epilepsy drug is engaging its target before it reaches patients?

Epilepsy is frequently a channelopathy, driven by faults in the sodium and potassium channels that act as the brain’s accelerator and brake. Yet around a third of people with epilepsy remain drug-resistant, and most current medicines were found through broad seizure models rather than designed against a specific mechanism. 

This article explores how sodium channel blockers and potassium channel openers work, and how genetics is steering development towards precision medicine. It also shows how TMS-EEG gives objective evidence of target engagement in healthy volunteers during Phase 1, supporting dose selection and replacing slow, seizure-diary endpoints. Limitations, including translation to patients and the need for standardised protocols, are also discussed.

Ion Channels: The Brain’s Accelerator and Brake

Epilepsy is frequently caused by channelopathies: dysfunctions in ion channels that disrupt the delicate balance between neuronal excitation and inhibition. Sodium and potassium channels work in opposite ways to control electrical signalling in neurons, broadly acting as the brain’s accelerator and brake respectively, and problems with either can increase seizure risk.

Potassium channels are primary regulators of neuronal excitability, and both loss-of-function and gain-of-function variants are associated with different types of epilepsy. Voltage-gated potassium channels let K+ ions flow out of the neuron, causing repolarisation and hyperpolarisation, which ends the action potential and sets the resting membrane potential. If these channels fail to open, K+ cannot leave the cell, so the neuron stays depolarised for too long and fires too easily.

Conversely, in some condition’s potassium channels can be over-active, paradoxically triggering severe seizures. For example, a mutation that reduces the M-current causes neonatal epilepsies. Both types of genetic variant can disrupt channel kinetics, deactivation or conductance. Targeting potassium channels therefore allows researchers to harness the brain’s natural cellular braking system.

Voltage-gated sodium channels open to let Na+ ions enter the neuron, triggering membrane depolarisation and generating the rising phase of the action potential. Gain-of-function mutations make channels hyperactive or unable to inactivate properly, allowing excess sodium entry, so neurons fire excessively and discharge repeatedly. Loss-of-function mutations are primarily located in inhibitory interneurons, which then cannot fire properly. This removes inhibition from brain circuits and indirectly causes hyperexcitation.

Measuring Drug Effects with TMS-EEG

Sodium channel blockers reduce high-frequency neuronal firing. Single-pulse transcranial magnetic stimulation (TMS) typically shows this as a higher motor threshold and reduced cortical reactivity, so it can confirm that the drug is engaging its target in the brain. Potassium channel openers stabilise the resting membrane potential and make neurons harder to excite, which TMS combined with electroencephalography (EEG) can detect as a dampened evoked response and changes in cortical oscillations.

Comparing TMS-evoked potential (TEP) patterns and motor thresholds across drug classes may help show which mechanism is acting, supporting mechanism-based drug development. This demonstrates target engagement and pharmacodynamic effects in healthy volunteers, helping to select a dose before patient trials.

From Seizure Control to Precision Medicine

The move towards precision medicine starts with an unmet need: about a third of people with epilepsy live with drug-resistant seizures. Most antiseizure medications reduce excitation, boost GABA-mediated inhibition, or do both—blocking the accelerator, strengthening the brakes, or combining these effects.

Many were found through broad seizure models rather than designed against a specific mechanism. Potassium channel modulators offer another therapeutic route. Because seizures themselves can alter potassium channel function, fine-tuning these channels may offer a way to interrupt disease progression and prevent a single seizure event from becoming a chronic problem.

Genetics is helping to guide more targeted development: variants in KCNQ2, SCN1A and SCN2A link channel dysfunction to specific epilepsies. The distinction between gain-of-function and loss-of-function variants matters because they can require opposite treatment approaches; a sodium channel blocker may help some patients but worsen others. Precision medicine therefore seeks to match the drug mechanism to the patient’s variant.

Newer compounds target specific channel subtypes rather than blocking channels broadly, with the aim of stronger efficacy and fewer side effects such as dizziness, sedation and cognitive slowing. Advances in structural biology are making this rational approach to drug design more achievable.

Objective Biomarkers and New Treatment Approaches

Objective biomarkers are replacing slow endpoints. Seizure diaries need long trial periods and are affected by placebo response and unreliable reporting. TMS-EEG and quantitative EEG offer faster, objective measures of target engagement and cortical excitability, supporting smaller, shorter and more efficient trials. Patient stratification by genotype or excitability profile should raise success rates, and adaptive designs with early pharmacodynamic readouts help to drop ineffective drugs sooner.

Wearable devices and long-term EEG monitoring are also improving seizure detection and outcome measurement. Therapeutic approaches are converging as well: combining channel drugs with other pathways (for example GABA-A or endocannabinoid targets) may improve control in drug-resistant cases, and newer modalities such as antisense oligonucleotides and gene therapy aim to correct the underlying cause rather than only suppress seizures.

Outcomes Beyond Seizures

Outcomes now extend beyond seizure control to include cognition, mood, sleep and quality of life. The developmental and epileptic encephalopathies are a major focus, as early, targeted treatment may alter the course of the disease. Challenges that will shape the direction of the field include translating healthy-volunteer and animal data to patients, standardising biomarkers across trial sites, cost and access, small patient numbers in rare genetic epilepsies, and the long-term safety of novel and genetic therapies. Even so, advances in science are making epilepsy care more precise and more effective.

Delivering Phase 1 TMS-EEG Studies

Phase 1 trials are essential for understanding a new drug’s pharmacodynamics in healthy volunteers. They require rigid protocols and strict safety procedures. Because they are needed for a development programme, most sponsors find it faster, cheaper and lower risk to buy the capability than to build it.

Contracting out means the techniques are already installed and maintained, and that different techniques are readily available and already compatible, which cuts preparation time. A failed or unusable dataset from an inexperienced team can mean repeating the study, which is far more expensive than paying for experienced delivery. TMS-EEG is sensitive to artefacts, and clean recordings and valid analysis require people who do this routinely. Experienced groups have validated protocols for motor threshold, paired-pulse measures and TEPs, which improve data quality and consistently. [SR2] 

Limitations and Validation Needs

TMS carries a small seizure risk, so trained operators, screening procedures and emergency protocols are essential. Such groups also already have access to participants. The central challenge is translating measurable drug effects into meaningful patient benefit.

Findings in healthy volunteers may not translate directly to people with epilepsy, and TMS mainly samples accessible cortical areas, so deep or focal sources may be missed. Safety screening remains essential because TMS carries a small seizure risk in people with epilepsy. Standardised protocols and larger validation studies are still needed before TMS-EEG becomes a routine trial endpoint. Its promise is therefore as a tool to support mechanism-based development and dose selection, while patient trials establish whether those signals translate into better outcomes.

References

•      Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004;5:553-564.

•      Löscher W, Klitgaard H, Twyman RE, Schmidt D. New avenues for anti-epileptic drug discovery and development. Nat Rev Drug Discov 2013;12:757-776.

•      Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-319.

•      Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. N Engl J Med 2011;365:919-926.

•      Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug-resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010;51:1069-1077.

•      Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs. JAMA Neurol 2018;75:279-286.

•      Krauss GL, Klein P, Brandt C, et al. Safety and efficacy of adjunctive cenobamate in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol2020;19:38-48.

•      Sharma R, Nakamura M, Neupane C, et al. Positive allosteric modulation of GABA-A receptors by a novel antiepileptic drug cenobamate. Eur J Pharmacol 2020;879:173117. †

•      Brodie MJ, Lerche H, Gil-Nagel A, et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 2010;75:1817-1824.

•      French JA, Porter RJ, Perucca E, et al. Efficacy and safety of XEN1101 (azetukalner), a novel potassium channel opener, in adults with focal epilepsy: a phase 2b randomised clinical trial (X-TOLE). JAMA Neurol 2023. † (check volume and pages)

•      Johnson JP Jr, Focken T, Khakh K, et al. NBI-921352, a first-in-class, NaV1.6-selective sodium channel inhibitor that prevents seizures in Scn8a gain-of-function mice, and wild-type mice and rats. eLife 2022;11:e72468. †

•      Li X, Zhang Q, Guo P, et al. Molecular basis for ligand activation of the human KCNQ2 channel. Cell Res2021;31:52-61.